Date: 2018-02-28
Type of information: Product acquisition
Compound: engineered bacteriophage platform
Company: C3J Therapeutics (USA - CA) Synthetic Genomics (USA - CA)
Therapeutic area: Infectious diseases
Type agreement: product acquisition
Action mechanism: bacteriophage
Disease: multidrug-resistant bacterial infections
Details:
- • On February 28, 2018, C3J Therapeutics, a private biotechnology company focused on the development of novel targeted antimicrobials, and Synthetic Genomics, a leader in designing and programming biology for desired function, announced an agreement between the two companies to integrate SGI’s proprietary engineered bacteriophage (or phage) platform with C3J’s R&D programs addressing high unmet medical needs linked to infectious diseases.
- Clinical data for natural phage demonstrates the potential of phage therapy to treat multidrug-resistant bacterial infections. Engineered phage can solve inherent limitations of natural phage such as narrow host range and resistance development. The combination of SGI’s and C3J’s phage and antimicrobial programs will enable new product development opportunities, such as engineering bacteriophage to deliver a peptide payload to enhance the antimicrobial impact.
- As part of the agreement, C3J will acquire a corporate partnership with a U.S.-based multinational pharmaceutical company for an undisclosed indication and an unpartnered program targeting Pseudomonas aeruginosa, which C3J plans to advance to the clinic. In addition to cash payments for the deal, SGI will receive common shares of C3J when certain milestones have been achieved.
Financial terms:
Latest news:
Is general: Yes
